A Phase II Study of Irinotecan and Temozolomide in Combination with Existing High-Dose Chemotherapy for Patients Newly Diagnosed with Ewing Sarcoma

Protocol
13-068
Full Title
A Phase II Trial of Irinotecan and Temozolomide in Combination with Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients with Newly Diagnosed Ewing Sarcoma
Phase
II
Purpose

Irinotecan and temozolomide are drugs routinely used to treat patients with Ewing sarcoma whose cancer has returned. Patients with newly diagnosed Ewing sarcoma usually receive a standard regimen of five chemotherapy drugs in combination with surgery and/or radiation therapy. Yet the cancer sometimes returns despite this approach.

In this study, researchers want to determine if giving irinotecan and temozolomide along with the initial five-drug chemotherapy regimen reduces the risk of the cancer returning in infants, children, adolescents, and young adults newly diagnosed with Ewing sarcoma. This study will evaluate the safety and effectiveness of this treatment.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • This study is open to patients ages 1 to 40.
  • Patients must be newly diagnosed with Ewing sarcoma and may not have had prior treatment for this cancer.

For more information and to inquire about eligibility for this study, please contact Dr. Heather Magnan at 212-639-7937.

Disease(s)
Sarcomas: Ewing's Sarcoma
Sarcomas: Soft Tissue Sarcoma
Locations
Related Diseases

Cancer Clinical Trials: Personalizing for Each Patient

Join our experts for a discussion of clinical trials on November 18. Clinical trials can give patients access to new drugs and other treatments before they are widely available, but how do you know if a trial is right for you?

Learn more »